Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls

Bibliography

• Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133(6 Suppl):141S-59S
   PubMed Web of Science ®Google Scholar
• Rice L, Beiderlinden M, Hursting MJ. Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th edition. CRC Press, Boca Raton, FL; 2013. p. 356-87
   Google Scholar
• Greinacher A. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th edition. CRC Press, Boca Raton, FL; 2013. 388-428
   Google Scholar
• Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991;324(26):1865-75
   PubMed Web of Science ®Google Scholar
• Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126(3 Suppl):204S-33S
   PubMed Web of Science ®Google Scholar
• Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost 2011;9(Suppl 1):105-17
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: time for a fresh look. Thromb Haemost 2006;96(5):547-52
   PubMed Web of Science ®Google Scholar
• Takemoto CM, Streiff MB, Shermock KM, et al. Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol 2013;139(4):450-6
   PubMed Web of Science ®Google Scholar
• Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e24S-43S
   PubMed Web of Science ®Google Scholar
• Patriquin C, Crowther M. Antithrombotic agents. In: Kitchens CS, Konkle BA, Kessler CM, editors. Consultative hemostasis and thrombosis. 3rd edition. WB Saunders, Elsevier, Philadelphia, PA; 2013. p. 477-95
   Google Scholar
• Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy 2012;32(6):546-58
   PubMed Web of Science ®Google Scholar
• Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154(1):49-56
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th edn. CRC Press, Boca Raton, FL; 2013. p. 24-76
   Google Scholar
• Ranucci M, Isgrò G, Cazzaniga A, et al. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999;14(6):437-42
   PubMed Web of Science ®Google Scholar
• Goyoso JM. 5-Year incidence of thrombocytosis and the effect of heparin dose response and heparin requirements. J Extra Corp Technol 1999;31(4):184-90
   PubMedGoogle Scholar
• Levy JH. Heparin resistance and antithrombin: should it still be called heparin resistance? J Cardiothorac Vasc Anesth 2004;18(2):129-30
   PubMed Web of Science ®Google Scholar
• Levy JH, Sniecinski RM. Activated clotting times, heparin responses, and antithrombin: have we been wrong all these years? Anesth Analg 2010;111(4):833-5
   PubMed Web of Science ®Google Scholar
• Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 2010;149(4):613-19
   PubMed Web of Science ®Google Scholar
• Edson VR, Krivit W, White JG. Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 1967;70(3):463-70
   PubMedGoogle Scholar
• Rosborough TK. Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes that monitoring with the activated partial thromboplastin time. Pharmacotherapy 1999;19(6):760-6
   PubMed Web of Science ®Google Scholar
• Guervil DJ, Rosenberg AF, Winterstein AG, et al. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 2011;45(7-8):861-8
   PubMed Web of Science ®Google Scholar
• Hauser VM, Rozek SL. Effect of warfarin on the activated partial thromboplastin time. Drug Intell Clin Pharm 1986;20(12):964-7
   PubMedGoogle Scholar
• Fragmin® (dalteparin sodium injection) product monograph, Pfizer Canada Ltd., last revised 19 July 2010
   Google Scholar
• Warkentin TE. Coumarin-induced skin necrosis and venous limb gangrene. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC, editors. Hemostasis and thrombosis: basic principles and clinical practice. 6th edition. Lippincott Williams & Wilkins, Philadelphia; 2013. p. 1308-17
   Google Scholar
• Warkentin TE. Heparin-induced thrombocytopenia: igG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev 1996;10(4):249-58
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Gruel Y, et al. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011;9(12):2498-500
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003;121(4):535-55
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003;163(20):2518-24
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332(20):1330-5
   PubMed Web of Science ®Google Scholar
• Linkins LA, Lee DH. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th edition. CRC Press, Boca Raton, FL; 2013. p. 110-50
   Google Scholar
• Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 1994;71(2):247-51
   PubMed Web of Science ®Google Scholar
• Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood 2000;96(1):182-7
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Drug-induced immune-mediated thrombocytopenia—from purpura to thrombosis. N Engl J Med 2007;356(9):891-3
   PubMed Web of Science ®Google Scholar
• Greinacher A, Warkentin TE. Heparin-induced thrombocytopenia. In: Aird WC, editor. Endothelial Biomedicine. Cambridge University Press, Cambridge; 2007. p. 1344-51
   Google Scholar
• Rauova L, Arepally G, McKenzie SE, et al. Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia. J Thromb Haemost 2009;7(Suppl 1):249-52
   PubMedGoogle Scholar
• Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996;101(5):502-7
   PubMed Web of Science ®Google Scholar
• Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005;94(1):132-5
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A. Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 2009;8(2):129-44
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Elavathil LJ, Hayward CPM, et al. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997;127(9):804-12
   PubMed Web of Science ®Google Scholar
• Srinivasan AF, Rice L, Bartholomew JR, et al. Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med 2004;164(1):66-70
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sikov WM, Lillicrap DP. Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia. Am J Hematol 1999;62(1):44-8
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Bernstein RA. Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003;348(11):1067-9
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Agents for the treatment of heparin-induced thrombocytopenia. Hematol/Oncol Clin N Am 2010;24(4):755-75
   PubMed Web of Science ®Google Scholar
• Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341(8):586-92
   PubMed Web of Science ®Google Scholar
• Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009;145(1):24-33
   PubMed Web of Science ®Google Scholar
• Greinacher A, Völpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99(1):73-80
   PubMed Web of Science ®Google Scholar
• Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia (HAT) investigators. Circulation 1999;100(6):587-93
   PubMed Web of Science ®Google Scholar
• Lubenow N, Eichler P, Lietz T, Greinacher A; HIT Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia—results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005;3(11):2428-36
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 Suppl):340S-80S
   PubMed Web of Science ®Google Scholar
• Refludan Prescribing Information as of October 2002, Berlex Laboratories, Wayne, NJ
   Google Scholar
• Hacquard M, de Maistre E, Lecompte T. Lepirudin: is the approved dosing schedule too high? J Thromb Haemost 2005;3:2593-6
   PubMed Web of Science ®Google Scholar
• Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006;108(5):1492-6
   PubMed Web of Science ®Google Scholar
• Tschudi M, Lämmle B, Alberio L. Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients. Blood 2009;113(11):2402-9
   PubMed Web of Science ®Google Scholar
• Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost 2008;99(5):819-29
   PubMed Web of Science ®Google Scholar
• Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: real world issues. Semin Thromb Hemost 2011;37(6):653-63
   PubMed Web of Science ®Google Scholar
• Verhovsek M, Moffat KA, Hayward CPM. Laboratory testing for fibrinogen abnormalities. Am J Hematol 2008;83(12):928-31
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Craven S, et al. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation. Thromb Haemost 2005;94(5):958-64
   PubMed Web of Science ®Google Scholar
• Warkentin TE. How I diagnose and manage HIT. Hematology Am Soc Hematol Educ Program 2011;2011:143-9
   PubMedGoogle Scholar
• Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103(14):1838-43
   PubMed Web of Science ®Google Scholar
• Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163(15):1849-56
   PubMed Web of Science ®Google Scholar
• Stossel TP, Levy R. Intravascular coagulation associated with pneumococcal bacteremia and symmetrical peripheral gangrene. Arch Intern Med 1970;125(5):876-8
   PubMed Web of Science ®Google Scholar
• Molos MA, Hall JC. Symmetrical peripheral gangrene and disseminated intravascular coagulation. Arch Dermatol 1985;121(8):1057-61
   PubMed Web of Science ®Google Scholar
• Johansen K, Hansen ST Jr. Symmetrical peripheral gangrene (purpura fulminans) complicating pneumococcal sepsis. Am J Surg 1993;165(5):642-5
   PubMed Web of Science ®Google Scholar
• Sharma BD, Kabra SR, Gupta B. Symmetrical peripheral gangrene. Trop Doct 2004;34(1):2-4
   PubMed Web of Science ®Google Scholar
• Hayes MA, Yau EHS, Hinds CJ, Watson JD. Symmetrical peripheral gangrene: association with noradrenaline administration. Intensive Care Med 1992;18(7):433-6
   PubMed Web of Science ®Google Scholar
• Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286(15):1869-78
   PubMed Web of Science ®Google Scholar
• Kienast J, Juers M, Wiedermann CJ, et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006;4(1):90-7
   PubMed Web of Science ®Google Scholar
• Hoffmann JN, Wiedermann CJ, Juers M, et al. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006;95(5):850-6
   PubMed Web of Science ®Google Scholar
• Horvatits T, Trauner M, Fuhrmann V. Hypoxic liver injury and cholestasis in critically ill patients. Curr Opin Crit Care 2013;19(2):128-32
   PubMed Web of Science ®Google Scholar
• Henrion J. Hypoxic hepatitis. Liver Int 2012;32(7):1039-52
   PubMed Web of Science ®Google Scholar
• Raurich JM, Pérez O, Llompart-Pou JA, et al. Incidence and outcome of ischemic hepatitis complicating septic shock. Hepatol Res 2009;39(7):700-5
   PubMed Web of Science ®Google Scholar
• Whitehead MW, Hawkes ND, Hainsworth I, Kingham JG. A prospective study of the causes of notably raises aspartate aminotransferase of liver origin. Gut 1999;45(1):129-33
   PubMed Web of Science ®Google Scholar
• Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med 2000;109(2):109-13
   PubMed Web of Science ®Google Scholar
• Siegal DM, Cook RJ, Warkentin TE. Acute hepatic necrosis and ischemic limb necrosis. N Engl J Med 2012;367(9):879-81
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Cuker A. Differential diagnosis of heparin-induced thrombocytopenia and scoring systems. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 5th edition. CRC Press, Boca Raton, FL; 2013. p. 77-109
   Google Scholar
• Takemitsu T, Wada H, Hatada T, et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost 2011;105(1):40-4
   PubMed Web of Science ®Google Scholar
• Soysal D, Çevik C, Saklamaz A, et al. Coagulation disorders secondary to acute liver failure in Amanita phalloides poisoning: a case report. Turk J Gastroenterol 2006;17(3):198-202
   PubMedGoogle Scholar
• Warkentin TE. Heparin-induced thrombocytopenia in critically ill patients. Crit Care Clin 2011;27(4):805-23
   PubMed Web of Science ®Google Scholar
• Love JE, Ferrell C, Chandler WL. Monitoring direct thrombin inhibitors with a plasma diluted thrombin time. Thromb Haemost 2007;98:234-42
   PubMed Web of Science ®Google Scholar
• Wanat MA, Hart SR, Putney D, et al. Alternative monitoring of argatroban using plasma-diluted thrombin time. Ann Pharmacother 2013;47(4):e18
   Google Scholar